ScholarIQanswers from OpenAlex
China Pharmaceutical University
InstitutionResearch output, impact & collaborations
China Pharmaceutical University is a institution indexed in ScholarIQ from OpenAlex.
What is known about China Pharmaceutical University?
ScholarIQrecord summary
China Pharmaceutical University is a research organisation in Nanjing, CN. OpenAlex records 39,318 works and 3,638,220 citations for it. 14,710 researchers list it as their most recent affiliation.
How many works does China Pharmaceutical University have?
ScholarIQindexed works
China Pharmaceutical University has 39,318 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does China Pharmaceutical University have?
ScholarIQcitation count
China Pharmaceutical University has 3,638,220 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at China Pharmaceutical University?
ScholarIQresearcher count
China Pharmaceutical University has 14,710 researchers in the ScholarIQ index.
What is the average h-index at China Pharmaceutical University?
ScholarIQavg h-index
China Pharmaceutical University has an average h-index of 56.5 in OpenAlex.
What is the ROR of China Pharmaceutical University?
ScholarIQror
The ROR for China Pharmaceutical University is on the source record.
What is the OpenAlex record for China Pharmaceutical University?
ScholarIQopenalex
The OpenAlex for China Pharmaceutical University is on the source record.
What is the Wikidata of China Pharmaceutical University?
ScholarIQwikidata
The Wikidata for China Pharmaceutical University is on the source record.
Who are the most-cited researchers behind China Pharmaceutical University?
ScholarIQtop researchers by citations
What are the most-cited papers on China Pharmaceutical University?
ScholarIQmost cited works
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, J. Nam, Sofía Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Christopher D. Buckley, Frank Buttgereit, Vivian P. Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan J. Gómez‐Reino, Laure Gossec, J.-E. Gottenberg, Johanna M W Hazes, T. Huizinga, Meghna Jani, Д. Е. Каратеев, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher J Edwards, Kimme L Hyrich, Janet Pope, Savia de Souza, Tanja Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Myrna Cardiel, Katerina Chatzidionysiou, Cătălin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques‐Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Rui‐Hua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun, Liwei Wang, Leizhen Zheng, Hong Guo, Jingbo Wu, Nong Xu, Jianwei Yang, Honggang Zhang, Ying Cheng, Ningju Wang, Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu
How much of the research on China Pharmaceutical University is open access?
ScholarIQopen access share
75%OPEN ACCESS